Start triage first, then route to emergency care.
Need urgent help? Start triage first, then route to emergency care.
Roxee Medication Guide
Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.
Veterinary professional?
These are the reference facts Roxee uses on browse cards and quick facts.
Sponsor, product, and application records imported from Animal Drugs @ FDA.
openFDA reaction terms and case summaries are supporting evidence, not proof of causality.
Drug type: Generic ingredient • Generic profile • No FDA branded products linked
Species: Both
Manufacturer: Multiple FDA sponsors
Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.
Antiemetic used to prevent and treat vomiting (and motion sickness in dogs). Species commonly shown: Both, Dog, Cat.
Antiemetic used to prevent and treat vomiting (and motion sickness in dogs).
Oral / Injectable
Store per label; protect injectable from light.
Use caution with severe liver disease.
Pain at injection site, lethargy, diarrhea.
Choose a pet, confirm current or past, and optionally add reminder notes.
Sign in to save this medication to your pet profile.
Sign in to continueStart here first for the safest next-step summary before the deeper medication detail.
Used for:
For the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.
Dosing note:
Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.
What to watch for:
When to call the vet:
What to tell or ask your vet today:
A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.
Roxee has limited cited overview evidence for Maropitant Citrate; use the official documents and your veterinarian's instructions for product-specific decisions.
32 tracked reaction signals; 62 reported cases; 3 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.
Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.
Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.
Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.
Hepatomegaly (4 reports), Hypokalaemia (3 reports), Anaphylaxis (3 reports), Wobbliness (2 reports), Vocalisation (2 reports)
Digestive (1), Skin & allergy (1), Effectiveness (1), Other (29)
Dog (41 reports), Cat (21 reports)
Retriever - Labrador (2), Schnauzer - Miniature (1), Pug (1), ['Mastiff (unspecified)', 'Crossbred Canine/dog'] (1). These are report metadata, not proof that a breed is at higher risk.
Verify whether Maropitant Citrate fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.
Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.
Use caution with severe liver disease, Hepatomegaly, Hypokalaemia, Anaphylaxis
Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.
Review status / Updated / Sources
Review status: Clinical reviewer not listed
Updated: February 12, 2026, 7:40 PM UTC
Side effects to monitor:
Most reported reactions:
Emergency warning signs:
Source-backed clinical checkpoints for quick review.
Official label facts first, then secondary summaries. Marketing content is separated below.
Use caution with severe liver disease.
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.
Received 2026-03-17 · MSK · MSK
Received 2026-03-16 · MSK · MSK
Received 2026-03-16 · MSK · MSK
Received 2026-02-27 · MSK · MSK
Received 2026-02-09 · MSK · MSK
Received 2026-01-27 · MSK · MSK
Received 2026-01-20 · MSK · MSK
Received 2025-12-11 · MSK · MSK
Received 2025-11-14 · MSK · MSK
Received 2025-11-14 · MSK · MSK
Received 2025-11-03 · MSK · MSK
Tap or hover a reaction to see what it means in plain language.
| Reaction | Body system | Cases | Species | Serious cases |
|---|---|---|---|---|
| Other | 4 | Cat | 0 | |
| Other | 3 | Cat | 0 | |
| Other | 3 | Dog | 0 | |
| Other | 2 | Cat | 0 | |
| Other | 2 | Dog | 0 | |
| Other | 2 | Dog | 0 | |
| Other | 2 | Cat | 0 | |
| Other | 2 | Dog | 0 |
Species coverage: Dog (41) Cat (21)
| Reaction | Body system | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|---|
| Other | Cat | Unknown | - | 4 | |
| Other | Cat | Unknown | - | 3 | |
| Other | Dog | Unknown | - | 3 | |
| Other | Cat | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Other | Cat | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Effectiveness | Dog | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Skin & allergy | Dog | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Other | Cat | Unknown | - | 2 | |
| Digestive | Dog | Unknown | - | 2 | |
| Other | Dog | Unknown | - | 2 | |
| Other | Cat | Unknown | - | 2 | |
| Other | Cat | Unknown | - | 2 | |
| Other | Cat | Unknown | - | 2 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Unknown | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Cat | Unknown | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 |
Store per label; protect injectable from light.
The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.
Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.
Full source previews and metadata remain in the veterinary/professional layer.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.
For Prevention of Acute Vomiting in dogs 2 - 7 months of age: Administer Maropitant Citrate Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.
For Prevention of Acute Vomiting in dogs 7 months of age and older: Administer Maropitant Citrate Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.
For Prevention of Vomiting due to motion sickness in dogs 4 months of age and older: Administer Maropitant Citrate Tablets orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the prevention and treatment of acute vomiting.
Administer 1.0 mg per kilogram (mg/kg) of body weight by subcutaneous or intravenous injection once daily for up to 5 consecutive days.
For the treatment of vomiting.
Administer 1.0 mg/kg of body weight by subcutaneous or intravenous injection once daily for up to 5 consecutive days.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.
For Prevention of Acute Vomiting in dogs 2 -7 months of age: Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.
For Prevention of Acute Vomiting in dogs 7 months of age and older: Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.
For Prevention of Vomiting due to motion sickness in dogs 4 months of age and older: Administer orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For prevention of acute vomiting.
Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.
For prevention of acute vomiting.
Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.
For prevention of vomiting due to motion sickness.
Administer orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
Quick facts and links to official labeling and safety signals.
Diagnosis-code mappings are not available for this medication yet.
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 11695-7029-1 | 11695 | - | |
| 11695-7029-2 | 11695 | - | |
| 11695-7030-1 | 11695 | - | |
| 11695-7030-2 | 11695 | - | |
| 11695-7031-1 | 11695 | - | |
| 11695-7031-2 | 11695 | - | |
| 11695-7032-1 | 11695 | - | |
| 11695-7032-2 | 11695 | - | |
| 11695-7054-1 | 11695 | - | |
| 11695-7054-2 | 11695 | - | |
| 11695-7055-1 | 11695 | - | |
| 11695-7055-2 | 11695 | - | |
| 11695-7056-1 | 11695 | - | |
| 11695-7056-2 | 11695 | - | |
| 11695-7057-1 | 11695 | - | |
| 11695-7057-2 | 11695 | - | |
| 13612-0035-0 | 13612 | - | |
| 13612-0035-1 | 13612 | - | |
| 17033-004-01 | 17033 | - | |
| 17033-006-04 | 17033 | - |
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
Every non-trivial field is expected to include provenance and update timestamps.
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
Maropitant Citrate Tablets
RX
Maropitant
Chewable Tablets
• Oral
|
Felix Pharmaceuticals Pvt. Ltd. | ANADA 200-833 | Approved | Feb 2, 2026 |
|
Maropitant Citrate
RX
Maropitant
Injectable Solution
• Intravenous, Subcutaneous
|
Dechra Veterinary Products LLC | ANADA 200-710 | Approved | Jan 5, 2026 |
|
Maropitant Citrate Tablets
RX
Maropitant
Tablet
• Oral
|
Felix Pharmaceuticals Pvt. Ltd. | ANADA 200-785 | Approved | Jul 1, 2024 |
|
Maropitant Citrate
RX
Maropitant
Tablet
• Oral
|
ZyVet Animal Health, Inc. | ANADA 200-747 | Approved | Mar 31, 2023 |
|
Cerenia® Tablets
RX
Maropitant
Tablet
• Oral
|
Zoetis Inc. | NADA 141-262 | Approved | Jan 31, 2019 |
|
Cerenia® Injectable Solution
RX
Maropitant
Liquid (Solution)
• Subcutaneous, Intravenous
|
Zoetis Inc. | NADA 141-263 | Approved | Jun 1, 2016 |
Data source: FDA Animal Drugs @ FDA (public search export).
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
For the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.
For Prevention of Acute Vomiting in dogs 2 - 7 months of age: Administer Maropitant Citrate Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.
For Prevention of Acute Vomiting in dogs 7 months of age and older: Administer Maropitant Citrate Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.
For Prevention of Vomiting due to motion sickness in dogs 4 months of age and older: Administer Maropitant Citrate Tablets orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days.
FDA page: Open in Animal Drugs @ FDA
For the prevention and treatment of acute vomiting.
Administer 1.0 mg per kilogram (mg/kg) of body weight by subcutaneous or intravenous injection once daily for up to 5 consecutive days.
For the treatment of vomiting.
Administer 1.0 mg/kg of body weight by subcutaneous or intravenous injection once daily for up to 5 consecutive days.
FDA page: Open in Animal Drugs @ FDA
For the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.
For Prevention of Acute Vomiting in dogs 2 -7 months of age: Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.
For Prevention of Acute Vomiting in dogs 7 months of age and older: Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.
For Prevention of Vomiting due to motion sickness in dogs 4 months of age and older: Administer orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days.
FDA page: Open in Animal Drugs @ FDA
For prevention of acute vomiting.
Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.
For prevention of acute vomiting.
Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.
For prevention of vomiting due to motion sickness.
Administer orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days.
FDA page: Open in Animal Drugs @ FDA
FDA page: Open in Animal Drugs @ FDA
FDA page: Open in Animal Drugs @ FDA
Antiemetic used to prevent and treat vomiting (and motion sickness in dogs).
Source: FDA Animal Drugs @ FDA • Reference
Use caution with severe liver disease.
Pain at injection site, lethargy, diarrhea.
Source: FDA openFDA • Reference
De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).
Showing top 5 for Digestive.
Showing top 5 for Skin & allergy.
Showing top 5 for Effectiveness.
Showing top 5 for Other.
Data source: FDA openFDA Animal & Veterinary adverse event reports.
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, Schnauzer - Miniature, Male, 5 year, 10.16 kilogram • Drug: MSK, Injection, Subcutaneous • Reactions: Lameness, Wobbliness, Tiredness (lethargy), Unable to walk, Weakness… • Outcome: Ongoing
Dog, Pug, Male, 3.75 year, 12.7 kilogram • Drug: MSK, Unknown • Reactions: Neurogenic keratoconjunctivitis sicca, Corneal ulcer, Nasal cavity disorder NOS, Abnormal Schirmer tear test • Outcome: Ongoing
Dog, ['Mastiff (unspecified)', 'Crossbred Canine/dog'], Male, 1 year, 29.574 kilogram • Drug: MSK, Tablet, Oral, Dose: 60 Milligram per animal, Frequency: 1 per day • Reactions: Hypotension, Not eating, Nausea, Drowsiness - systemic disorder, Pain NOS… • Outcome: Euthanized
Dog, Male, 12 year, 4.536 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 4.50 mL per dose, Frequency: 1 per day • Reactions: Lateral recumbency, Agonal breathing, Death • Outcome: Died
Cat, Domestic Longhair, Male, 5 month, 2.781 kilogram • Drug: MSK, Tablet, Oral, Dose: 8 Milligram per animal • Reactions: Increased respiratory rate, Breathing difficulty, Crackles on auscultation, Abnormal ultrasound finding, Pulmonary disorder NOS… • Outcome: Ongoing
Cat, Domestic Shorthair, Female, 19.7 week, 2.22 kilogram • Drug: MSK, Unknown • Reactions: Not himself/herself, Behavioral disorder (unspecified), Disorientation, Dilated pupils, Tiredness (lethargy)… • Outcome: Outcome Unknown
Dog, Retriever - Labrador, Male, 10 year, 28.576 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 2.90 mL per animal • Reactions: Limping, Limb weakness, Cough, Neurological signs NOS, Wobbliness… • Outcome: Ongoing
Dog, Retriever - Labrador, Male, 3 year, 28.576 kilogram • Drug: MSK, Tablet, Unknown • Reactions: Increased salivation, Drowsiness - systemic disorder • Outcome: Outcome Unknown
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose causes excessive drooling, lethargy, collapse due to low BP. Emergency care includes IV fluids, blood pressure support, and monitoring.
Store per label; protect injectable from light.
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.